
Sign up to save your podcasts
Or


A quick preview of Episode 3 of InnoBridge Podcast,
Gil Kerbs, Chief Investment Officer at Teuza Venture Capital and former Medtronic China executive, on why entering China’s lower-tier healthcare market is like an NBA player switching to soccer, how he became “the only person in the world” who could run that business, and why geography still matters even in venture capital.
Guest
Gil Kerbs is Chief Investment Officer at Teuza Venture Capital, one of Israel's oldest venture funds, where he invests in early-stage healthcare startups. Before Teuza, he spent seven years at Medtronic in China, eventually leading a 60-to-70-person business unit that grew revenue roughly 30% annually by penetrating the country's lower-tier hospital market — a division serving around 2,000 township and county hospitals. He holds a degree in Electrical Engineering from Technion and an MBA from Wharton's Lauder Institute. Alongside his VC role, he founded The Healthcare Bay, a nonprofit working to turn the greater Haifa region into Israel's dedicated healthcare innovation hub.
Episode Description
How do you convince a small-city hospital director to let you train his surgeons — when doing so might mean losing them to a bigger hospital in Shanghai? Gil Kerbs, now Chief Investment Officer at Teuza Venture Capital, spent seven years living that question as the person Medtronic's leadership called "the only person in the world" who could run its lower-tier China business.
Gil walks through what actually changes when a US medtech giant has to relearn the rules for China's smaller cities: pricing decisions where one or two dollars can be a month's wages, a management style built on the ability to say no to his own leadership, and the guanxi-driven trust that decides who a hospital will actually buy from.
He's just as direct about what came after Medtronic. As CIO at Teuza — founded in 1992, one of Israel's first venture funds — Gil now screens hundreds of healthcare startups a year, and shares two portfolio bets, EndoCure's robotic ultrasound system and TytoCare's remote exam device, as examples of what he looks for.
We also get into The Healthcare Bay, the nonprofit Gil founded to turn the Haifa region — already home to 100% of Israel's major med-tech R&D centers — into the country's answer to Boston in healthcare innovation, and why he believes geography still matters even in an industry that claims it doesn't.
We close with a lightning round covering Shanghai hotpot, an Israeli-invented compression algorithm, and the one time Gil's imperfect Chinese accidentally passed for a regional dialect.
Chapters
00:00 Cold Open (Hook Montage)
01:05 Full Intro & Welcome
02:00 From Technion to Medtronic: An Engineer's China Story
11:39 Leading Medtronic's China Lower-Tier Market Penetration
34:01 Teuza Venture Capital: History, Strategy, and Real Deals
46:57 Healthcare Bay: Building Haifa into Israel's Boston
54:27 China and Israel Healthcare: Where the Opportunity Lies
56:40 Lightning Round & Close
Companies Mentioned
Medtronic, Covidien, Teuza Venture Capital, EndoCure, TytoCare, Nova, Pitango, The Healthcare Bay, Technion, Rambam Hospital, Clalit
Follow / Share
If you found this conversation useful, forward it to one friend in the innovation ecosystem.
Why move a robotics startup from Tel Aviv to Shenzhen? Gal Goren, former CEO of temi Robotics & serial entrepreneur in deep tech, did exactly that — spending five years scaling the Israeli-born company to more than 20,000 units across 36countries. He's just as candid about the humanoid-robotics startup he built next, and had to shut down.
In this episode:
CHAPTERS
00:00 Cold Open
01:50 Full Intro & Welcome
02:50 Opening — “0 to 1 to 100”
05:15 First Trip to China
06:45 Why Shenzhen — The temi Case
12:23 Scaling & the Costliest Mistake
15:48 Fundraising — China vs. Israel
17:52 Cross-Cultural Team — “Gal, You're Wrong”
22:08 Advice for Founders Entering China
24:04 Intel — Building 0 to 1 Inside a Corporation
26:38 Advice for Corporate Innovators
28:11 The Failed Humanoid Robot Startup (Build AI)
31:44 Zoom Out: Five Years in China & the China-Israel Opportunity
36:11 Lightning Round
37:56 Sign-off
Key Quotes
“Shenzhen is the best place on earth to buildhardware... because you have a lot of talent, and within one hour's drive from the office, you have 100% of the supply chain.” —on why temi scaled in China
“It took me around two years to let my employeesunderstand this is my expectation from them: I want them to tell me what to do differently.” — on building trust with his Chinese team
“In a startup, you wake up in the morning and you aregoing to a war. In the corporate, you start the war — maybe let's start it in the afternoon.” — on 0-to-1 in a corporation vs. a startup
“Fail is something you're not standing up after. Ifyou stood up after, then probably you took something out of this unsuccessful journey.” — on Build AI, his failedhumanoid-robotics startup
“You need to carefully pick your investors, so youdon't waste time and resources on the wrong investors who can't invest in a startup that requires this much capital.” — the lesson from Build AI
Mentions & Resources
Companies: temi Robotics,Intel Corporation, Build AI
Book mentioned: a biography of Menachem Begin — the book Gal names as one every innovator should read, for its portrait of someone pursuing a vision with total conviction
Places: Shenzhen (Shekou, Nanshan, Bao'an), Tel Aviv
Follow / Share
If you found this conversation useful, forward it to one friend in the innovation ecosystem.New InnoBridge episodes every two weeks — subscribe on YouTube, Apple Podcasts, or Spotify.
If you work in hardware, robotics, or cross-border dealmaking between China and Israel, this one's for you.
AION Labs CEO Mati Gill explains how he brought four rival pharma giants — Pfizer, AstraZeneca, Merck, and Teva — intoone venture studio, the acquisition story behind CombinAble.AI, and the failure that taught him to always invest in Hybrid team. He also revisits his years leading Teva's China market entry, from Austedo's approval to what he'd tell any founder heading into the Chinese market today.
Guest
Mati Gill is CEO and Founder of AION Labs,a venture studio backed by Pfizer, AstraZeneca, Merck, and Teva that builds AI-for-pharma startups from the ground up. Before AION Labs, he held multiple senior leadership roles at Teva Pharmaceuticals — including leading the government-relations effort behind Teva's China market entry — and in Israel's public sector. He also sits on the board of the Israel Export Institute andseveral ventures.
Chapters
00:00 Cold Open
01:01 A Typical Work Week
01:44 What Is AION Labs
04:47 Case 1: CombinAble.AI
11:27 What Makes a Founder — and Coachability
16:13 Origin Story: Four Rival Pharma Giants, One Room
22:31 Failure Case: The Non-Hybrid Founders
27:17 AI's Future in Pharma, and “The Man in the Arena”
31:55 Case 2: Teva's China Market Entry
41:43 Zoom Out: China's Biotech Rise, Israel's Opportunity
45:57 Lightning Round
49:01 Sign-off
From the publisher's feed